An emerging trend in Canada is the use of biosimilars as a cost-saving alternative treatment to biologics in rheumatology, gastroenterology, oncology, dermatology and other treatment areas. Recent policies across Canada suggest that biosimilars will soon be entering the field of ophthalmology, however there are currently no guidelines and clinical data available on the appropriate use when it comes to vision loss treatment.
While biosimilars may be an emerging treatment option in ophthalmology, there remain concerns on the limited guidelines and patient education. Should biosimilars be an alternative in the future in the treatment of retinal diseases in the future, patients and health care providers must be equipped with the latest current evidence-based information.
The time to raise awareness about biosimilars in ophthalmology is now.
What is a Biosimilar?
Currently there are significant knowledge gaps among older adults, patients and their caregivers, patient and advocacy organization as well as professional organizations regarding biosimilars in ophthalmology. The videos below are not intended to replace the knowledge gained in a thorough consultation with a health care professional, but may provide a an overview of biosimilars and are key resources in the national biosimilars discourse.
The Gastrointestinal Society, a registered Canadian charity, provides trusted, evidence-based information on all areas of the gastrointestinal tract, and is committed to improving the lives of people with GI and liver conditions, supporting research, advocating for appropriate patient access to health care, and promoting gastrointestinal and liver health.
The Canadian Arthritis Patient Alliance (CAPA) is a volunteer based organization comprised of people across the country who live with some form of arthritis. CAPA works to educate and empower people living with arthritis by collecting and producing patient resources and policy papers, and through outreach projects.